10-Q · May 14, 2026
Cardiff Oncology reported a significant decline in revenues in Q1 2026, totaling $41,000, compared to $109,000 in Q1 2025. The gross margin remained steady at 100%, but the company reported continued substantial…
Earnings analysis · 10-Q
CRDF earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract provides no current-quarter income statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so financial trends cannot be independently assessed from the filing text…
Read full summary
The supplied 10-Q extract provides no current-quarter income statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so financial trends cannot be independently assessed from the filing text provided. The principal update is a substantial escalation in legal and operational risk: Cardiff is litigating 1 dispute with NMS over rights integral to onvansertib. Loss of those rights, inability to obtain injunctive relief, and litigation that may last multiple years could materially disrupt operations, increase costs, and impair financing flexibility.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls were effective as of June 30, 2026, providing reasonable assurance that required information was reported within SEC time periods.
-
No material control changes
The company reported no change in internal control over financial reporting during the 3 months ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, those controls.
What to watch
-
Pending NMS litigation threatens license
The 10-Q adds material litigation risk relating to 1 pending lawsuit against NMS. The company states that an adverse determination could result in loss of the licensed rights and materially affect its business, financial condition, results of operations, and prospects.
-
Potential loss of onvansertib rights
The filing states that the NMS Agreement provided exclusive rights integral to onvansertib and that termination could require the company to cease or significantly curtail operations, seek alternative technology, or impair related assets.
-
Prolonged litigation may consume cash
The company says the litigation could take multiple years at the trial-court level, with additional time for appeals, while also generating significant legal fees and diverting senior-management resources.
Management's outlook
The supplied 10-Q extract does not include MD&A, financial statements, or a quantitative outlook. Prior cash-runway commentary from the July 16, 2026 8-K is not reaffirmed in the supplied filing.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.